5:25 PM ET
8-K
Capital Raise
Annovis Bio Capital Raise of $21M
Annovis Bio entered into an underwriting agreement to raise approximately $21.0 million through a public offering of 19,000,000 shares of common stock and 2,000,000 pre-funded warrants, accompanied by warrants to purchase an additional 21,000,000 shares. The company intends to use the proceeds for the clinical development of its lead compound, Buntanetap, in studies for Alzheimer’s and Parkinson’s disease.
- Value
- $21M
- Counterparty
- Canaccord Genuity LLC